ArticleEuropean heart journal. Cardiovascular Imaging2026
Prevalence and determinants of asymmetric septal hypertrophy (ASH) in diseases of left ventricular hypertrophy (LVH).
Article in European heart journal. Cardiovascular Imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
24 authors.
Funding
Abstract
aimsTo determine the prevalence of asymmetric septal hypertrophy (ASH) across health and in diseases associated with left ventricular hypertrophy (LVH), including hypertrophic cardiomyopathy (HCM). METHODS AND
resultsWe analysed two complementary datasets. First, a large UK Biobank healthy reference cohort (n = 4020) was used to model demographic determinants of septal-to-lateral wall thickness ratio (SLR) and to provide the reference group for age-, sex-, and body surface area-adjusted comparisons. Second, a multi-cohort clinical CMR dataset included 1655 subjects comprising local healthy volunteers, athletes, patients with hypertension, aortic stenosis, Fabry disease, amyloid light chain (AL) amyloidosis, amyloid transthyretin (ATTR) amyloidosis, and HCM. LVH was defined by maximum wall thickness (MWT) ≥15 mm and asymmetry defined as SLR≥1.3. Left ventricular morphology was classified as normal, asymmetric remodelling (SLR≥1.3; MWT<15 mm), symmetric hypertrophy (SLR<1.3; MWT≥15 mm) or ASH (SLR≥1.3; MWT≥15 mm). ASH was highly prevalent in HCM (61%) but was also observed in ATTR amyloidosis (37%), AS (26%), and AL amyloidosis (23%). In the healthy reference cohort, a higher septal-to-lateral ratio was independently associated with older age, female sex, and larger body surface area (P < 0.001). After adjustment for these demographic factors, only HCM retained a clinically meaningful excess in septal asymmetry (ΔSLR = +0.27; P < 0.001). In contrast, the apparent asymmetry in non-HCM cohorts was partly explained by demographic variation. After adjustment, only HCM showed a clinically meaningful excess in SLR, whereas other disease cohorts showed either no material difference or small negative differences relative to healthy controls.
conclusionASH is a common but non-specific finding in diseases associated with LVH. Septal asymmetry increases with age and body-size and is more pronounced in women. After adjusting for age, sex, and body-size, disproportionate septal asymmetry was most characteristic of HCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.